Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2011 June;36(2) > Minerva Endocrinologica 2011 June;36(2):147-56

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

  PREDIABETES AND THE METABOLIC SYNDROME


Minerva Endocrinologica 2011 June;36(2):147-56

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?

Sathyapalan T., Atkin S. L.

Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK


PDF  


There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.

top of page

Publication History

Cite this article as

Corresponding author e-mail

thozhukat.sathyapalan@hyms.ac.uk